FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024459752> ?p ?o ?g. }

• W2024459752 endingPage "A229" @default.
• W2024459752 startingPage "A229" @default.
• W2024459752 abstract "To assess the clinical characteristics of patients with RA receiving their first biologic in 5EU. A multi-country multi-center medical chart-review study of RA patients was conducted among physicians (rheumatologists:97%) in hospitals and private practices to collect de-identified data on patients who were recently treated with a biologic as part of usual care. Physicians were screened for duration of practice (3-30 yrs) and patient volume (incl. >2RA biologic patients/week) and recruited from a large panel to be geographically representative in each country. Eligible patient charts (>5) were randomly selected from a sample of prospective patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status. In 1Q2012, 2208 eligible RA patient charts were abstracted; 1562 (71%) patients were on their first biologic (mean-age:50.7yrs, female:71%). Geographic distribution of patients were - UK:19%, Germany:18%, France:22%, Italy:23%, Spain:18%. Time-to-1stbiologic from diagnosis (range:31mo (Italy)-52mo (France)) and time-on-current biologic (range:17month (Italy)-27month (France)) differed within 5EU. The top-3 reasons for biologic treatment initiation were consistent across 5EU (‘mechanism of action’, ‘improve signs/symptoms’, ‘prevent structural damage’), whereas the next 2 reasons differed (UK/Germany: ‘disease worsened’ & ‘positive personal experience’; France: ‘inhibits disease’ & ‘mode of administration’; Italy: ‘frequency of administration’ & ‘positive personal experience’; Spain: ‘positive personal experience’ & ‘inhibits disease progression’). Key lab measures documented were: ESR (range:20.8mm/h (France)-29.1mm/h (Italy)) and CRP (range:6.9mg/dl (Spain)-15.0mg/dl (UK)). Current disease severity per physician-judgment (mild:moderate:severe) in 5EU were: UK-58%:29%:13%, Germany-50%:44%:7%, France-39%:48%:12%, Italy-47%:49%:4%, Spain-59%:36%:5%. Among patients with available data, current HAQ (range: 0.7(Spain)-1.5(Germany)), DAS28 (range:3.0(Spain)-3.8(Germany)), 100mmVAS (range:23.3(France)-34.8(Italy)) and Total Sharp (range:0.9(France)-(3.6(Germany)) differed within 5EU. Among RA patients receiving their first biologic, disease severity differed within 5EU, with patients in Germany with relatively higher burden. Impact of specific biologic treatments on the observed patterns warrants further scrutiny." @default.
• W2024459752 created "2016-06-24" @default.
• W2024459752 creator A5014304265 @default.
• W2024459752 creator A5051981465 @default.
• W2024459752 creator A5076016430 @default.
• W2024459752 creator A5077951223 @default.
• W2024459752 date "2013-05-01" @default.
• W2024459752 modified "2023-10-14" @default.
• W2024459752 title "Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis (Ra) Receiving Their First Biologic In Uk, Germany, France, Italy And Spain (5eu)" @default.
• W2024459752 doi "https://doi.org/10.1016/j.jval.2013.03.1161" @default.
• W2024459752 hasPublicationYear "2013" @default.
• W2024459752 type Work @default.
• W2024459752 sameAs 2024459752 @default.
• W2024459752 citedByCount "0" @default.
• W2024459752 crossrefType "journal-article" @default.
• W2024459752 hasAuthorship W2024459752A5014304265 @default.
• W2024459752 hasAuthorship W2024459752A5051981465 @default.
• W2024459752 hasAuthorship W2024459752A5076016430 @default.
• W2024459752 hasAuthorship W2024459752A5077951223 @default.
• W2024459752 hasBestOaLocation W20244597521 @default.
• W2024459752 hasConcept C126322002 @default.
• W2024459752 hasConcept C144024400 @default.
• W2024459752 hasConcept C149923435 @default.
• W2024459752 hasConcept C187212893 @default.
• W2024459752 hasConcept C195910791 @default.
• W2024459752 hasConcept C2777575956 @default.
• W2024459752 hasConcept C2779134260 @default.
• W2024459752 hasConcept C512399662 @default.
• W2024459752 hasConcept C71924100 @default.
• W2024459752 hasConceptScore W2024459752C126322002 @default.
• W2024459752 hasConceptScore W2024459752C144024400 @default.
• W2024459752 hasConceptScore W2024459752C149923435 @default.
• W2024459752 hasConceptScore W2024459752C187212893 @default.
• W2024459752 hasConceptScore W2024459752C195910791 @default.
• W2024459752 hasConceptScore W2024459752C2777575956 @default.
• W2024459752 hasConceptScore W2024459752C2779134260 @default.
• W2024459752 hasConceptScore W2024459752C512399662 @default.
• W2024459752 hasConceptScore W2024459752C71924100 @default.
• W2024459752 hasIssue "3" @default.
• W2024459752 hasLocation W20244597521 @default.
• W2024459752 hasOpenAccess W2024459752 @default.
• W2024459752 hasPrimaryLocation W20244597521 @default.
• W2024459752 hasRelatedWork W2041279917 @default.
• W2024459752 hasRelatedWork W2082406232 @default.
• W2024459752 hasRelatedWork W2156283049 @default.
• W2024459752 hasRelatedWork W2316954211 @default.
• W2024459752 hasRelatedWork W2326094713 @default.
• W2024459752 hasRelatedWork W2327246029 @default.
• W2024459752 hasRelatedWork W2427075784 @default.
• W2024459752 hasRelatedWork W2761967325 @default.
• W2024459752 hasRelatedWork W3142209233 @default.
• W2024459752 hasRelatedWork W4245782456 @default.
• W2024459752 hasVolume "16" @default.
• W2024459752 isParatext "false" @default.
• W2024459752 isRetracted "false" @default.
• W2024459752 magId "2024459752" @default.
• W2024459752 workType "article" @default.